Practical aspects of etomidate use in the management of hypercortisolaemia

Veronica A. Preda, Ashley B. Grossman*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

We appreciate the letter from of Dr Soh et al . regarding our review on the use of etomidate in the treatment of Cushing's syndrome.We note that in their experience, our recommended dose regimen of 2.5 mg/h or thereabouts appears to be a safe and effective starting dose in most patients, and we note the utility and ease of use of the lipid formulation and its relative freedom from side effects compared with the more commonly used propylene glycol formulation; these are very helpful comments. Their experience in treating a further four patients is indeed further evidence of the usefulness of this agent.

Original languageEnglish
Pages (from-to)729
Number of pages1
JournalEuropean Journal of Endocrinology
Volume167
Issue number5
DOIs
Publication statusPublished - Nov 2012
Externally publishedYes

Fingerprint Dive into the research topics of 'Practical aspects of etomidate use in the management of hypercortisolaemia'. Together they form a unique fingerprint.

Cite this